Physician profile
Mishel Simoni
NPI 1447836549
$803.00
in general payments reported to CMS, 2019-2025
12 companies · $627 in 2025
The $627 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $176 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $803.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $803.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $237.47 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $155.05 | 2024-2025 | |
| Abbott Laboratories | $69.27 | 2024-2025 | Freestyle Libre 3 |
| Novo Nordisk INC | $62.42 | 2025 | Wegovy |
| Pfizer INC. | $62.41 | 2024-2025 | |
| Lilly USA, LLC | $47.92 | 2024-2025 | Zepbound, Mounjaro |
| Astrazeneca Pharmaceuticals Lp | $45.69 | 2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $40.86 | 2024-2025 | Ofev, Jardiance |
| Exact Sciences Corporation | $32.40 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $17.75 | 2025 | Rexulti |
| Merck Sharp & Dohme LLC | $16.76 | 2025 | Gardasil 9, Capvaxive |
| Cequr Corporation | $15.00 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mishel Simoni listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.